Market Cap 1.84B
Revenue (ttm) 465.31M
Net Income (ttm) -44.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9.61%
Debt to Equity Ratio 0.13
Volume 361,600
Avg Vol 506,404
Day's Range N/A - N/A
Shares Out 49.72M
Stochastic %K 14%
Beta 1.40
Analysts Strong Sell
Price Target $52.78

Company Profile

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias;...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 513 755 4100
Fax: 513 755 4567
Address:
7555 Innovation Way, Mason, United States
SuperGreenToday
SuperGreenToday Jan. 26 at 2:55 PM
$ATRC Share Price: $39.12 Contract Selected: Jul 17, 2026 $40 Calls Buy Zone: $6.12 – $7.56 Target Zone: $11.07 – $13.53 Potential Upside: 71% ROI Time to Expiration: 171 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 22 at 2:04 PM
$ATRC Current Stock Price: $39.27 Contracts to trade: $40 ATRC Feb 20 2026 Call Entry: $1.35 Exit: $1.83 ROI: 36% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 13 at 9:47 PM
$ATRC RSI: 27.66, MACD: 0.2497 Vol: 1.39, MA20: 40.42, MA50: 37.52 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
JarvisFlow
JarvisFlow Dec. 16 at 3:36 PM
JP Morgan updates rating for AtriCure ( $ATRC ) to Overweight, target set at 42 → 48.
0 · Reply
10xStacks
10xStacks Dec. 12 at 5:46 PM
1 · Reply
ZacksResearch
ZacksResearch Dec. 12 at 4:21 PM
$ATRC unveils breakthrough dual-energy platform in surgical ablation! 🚀 📈 First patients successfully treated, advancing ATRC's platform toward a planned clinical trial next year. 🩺 Year-to-date shares up 35.5%, outshining industry’s 1.1% growth. 🔍 Zacks Rank #2 (Buy) signals bullish momentum. See what this means for ATRC's future growth 👉 https://www.zacks.com/stock/news/2803792/atrc-treats-first-patients-using-novel-dual-energy-pfa-rfa-platform?cid=sm-stocktwits-2-2803792-body-24653&ADID=SYND_STOCKTWITS_TWEET_2_2803792_BODY_24653
0 · Reply
ZacksResearch
ZacksResearch Dec. 12 at 3:21 PM
Big milestone alert for $ATRC 🚀 ATRC just treated its first patients with its dual-energy PFA-RFA platform — a meaningful step as it moves toward a clinical trial next year. That’s the kind of early traction investors watch closely. Full details here 👉 https://www.zacks.com/stock/news/2803792/atrc-treats-first-patients-using-novel-dual-energy-pfa-rfa-platform?cid=sm-stocktwits-2-2803792-teaser-24638&ADID=SYND_STOCKTWITS_TWEET_2_2803792_TEASER_24638
0 · Reply
Arcides
Arcides Nov. 30 at 5:35 PM
$ATRC chart is a mess, too much volatility, was this a shakeout?
0 · Reply
RunnerSignals
RunnerSignals Nov. 20 at 8:46 PM
mini-pulse pop! $AMZN $APTV $AR $ATRC $CYBR all waking up some bouncing some breaking and some just teasing. charts heating up… https://stocksrunner.com/news/2025-11-20-daily-market-pulse-advanced-technical-analysis
0 · Reply
maq34
maq34 Nov. 7 at 3:56 PM
$ATRC Raised 2025 Financial Outlook: Building on the strong results, AtriCure raised its full-year 2025 revenue projection to a range of $532 million to $534 million, and its adjusted EBITDA forecast to between $55 million and $57 million. PT of $54 and up…! $AMGN $ABBV $VRTX $GILD
0 · Reply
Latest News on ATRC
AtriCure, Inc. (ATRC) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 11:16 PM EDT - 3 months ago

AtriCure, Inc. (ATRC) Q3 2025 Earnings Call Transcript


AtriCure to Participate in Upcoming Investor Conferences

Oct 27, 2025, 8:00 AM EDT - 3 months ago

AtriCure to Participate in Upcoming Investor Conferences


AtriCure to Announce Third Quarter 2025 Financial Results

Oct 8, 2025, 8:00 AM EDT - 4 months ago

AtriCure to Announce Third Quarter 2025 Financial Results


AtriCure, Inc. (ATRC) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 7:14 PM EDT - 6 months ago

AtriCure, Inc. (ATRC) Q2 2025 Earnings Call Transcript


AtriCure to Announce Second Quarter 2025 Financial Results

Jul 8, 2025, 8:00 AM EDT - 7 months ago

AtriCure to Announce Second Quarter 2025 Financial Results


AtriCure, Inc. (ATRC) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 9:34 PM EDT - 9 months ago

AtriCure, Inc. (ATRC) Q1 2025 Earnings Call Transcript


AtriCure Reports First Quarter 2025 Financial Results

Apr 29, 2025, 4:01 PM EDT - 9 months ago

AtriCure Reports First Quarter 2025 Financial Results


AtriCure Announces First Use of the AtriClip PRO-Mini® Device

Apr 10, 2025, 8:00 AM EDT - 10 months ago

AtriCure Announces First Use of the AtriClip PRO-Mini® Device


AtriCure to Announce First Quarter 2025 Financial Results

Apr 8, 2025, 8:00 AM EDT - 10 months ago

AtriCure to Announce First Quarter 2025 Financial Results


AtriCure to Host Analyst & Investor Day on March 26, 2025

Mar 12, 2025, 8:00 AM EDT - 11 months ago

AtriCure to Host Analyst & Investor Day on March 26, 2025


AtriCure, Inc. (ATRC) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 10:46 PM EST - 1 year ago

AtriCure, Inc. (ATRC) Q4 2024 Earnings Call Transcript


AtriCure, Inc. (ATRC) Q3 2024 Earnings Call Transcript

Oct 29, 2024, 11:53 PM EDT - 1 year ago

AtriCure, Inc. (ATRC) Q3 2024 Earnings Call Transcript


AtriCure Reports Third Quarter 2024 Financial Results

Oct 29, 2024, 4:01 PM EDT - 1 year ago

AtriCure Reports Third Quarter 2024 Financial Results


AtriCure to Announce Third Quarter 2024 Financial Results

Oct 8, 2024, 8:00 AM EDT - 1 year ago

AtriCure to Announce Third Quarter 2024 Financial Results


AtriCure Receives CE-Mark for the EnCompass® Clamp

Oct 1, 2024, 8:00 AM EDT - 1 year ago

AtriCure Receives CE-Mark for the EnCompass® Clamp


AtriCure, Inc. (ATRC) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 12:01 AM EDT - 1 year ago

AtriCure, Inc. (ATRC) Q2 2024 Earnings Call Transcript


AtriCure Reports Second Quarter 2024 Financial Results

Jul 30, 2024, 4:01 PM EDT - 1 year ago

AtriCure Reports Second Quarter 2024 Financial Results


AtriCure to Announce Second Quarter 2024 Financial Results

Jul 9, 2024, 8:00 AM EDT - 1 year ago

AtriCure to Announce Second Quarter 2024 Financial Results


AtriCure, Inc. (ATRC) Q1 2024 Earnings Call Transcript

May 2, 2024, 1:48 AM EDT - 1 year ago

AtriCure, Inc. (ATRC) Q1 2024 Earnings Call Transcript


AtriCure Reports First Quarter 2024 Financial Results

May 1, 2024, 4:01 PM EDT - 1 year ago

AtriCure Reports First Quarter 2024 Financial Results


SuperGreenToday
SuperGreenToday Jan. 26 at 2:55 PM
$ATRC Share Price: $39.12 Contract Selected: Jul 17, 2026 $40 Calls Buy Zone: $6.12 – $7.56 Target Zone: $11.07 – $13.53 Potential Upside: 71% ROI Time to Expiration: 171 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 22 at 2:04 PM
$ATRC Current Stock Price: $39.27 Contracts to trade: $40 ATRC Feb 20 2026 Call Entry: $1.35 Exit: $1.83 ROI: 36% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 13 at 9:47 PM
$ATRC RSI: 27.66, MACD: 0.2497 Vol: 1.39, MA20: 40.42, MA50: 37.52 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
JarvisFlow
JarvisFlow Dec. 16 at 3:36 PM
JP Morgan updates rating for AtriCure ( $ATRC ) to Overweight, target set at 42 → 48.
0 · Reply
10xStacks
10xStacks Dec. 12 at 5:46 PM
1 · Reply
ZacksResearch
ZacksResearch Dec. 12 at 4:21 PM
$ATRC unveils breakthrough dual-energy platform in surgical ablation! 🚀 📈 First patients successfully treated, advancing ATRC's platform toward a planned clinical trial next year. 🩺 Year-to-date shares up 35.5%, outshining industry’s 1.1% growth. 🔍 Zacks Rank #2 (Buy) signals bullish momentum. See what this means for ATRC's future growth 👉 https://www.zacks.com/stock/news/2803792/atrc-treats-first-patients-using-novel-dual-energy-pfa-rfa-platform?cid=sm-stocktwits-2-2803792-body-24653&ADID=SYND_STOCKTWITS_TWEET_2_2803792_BODY_24653
0 · Reply
ZacksResearch
ZacksResearch Dec. 12 at 3:21 PM
Big milestone alert for $ATRC 🚀 ATRC just treated its first patients with its dual-energy PFA-RFA platform — a meaningful step as it moves toward a clinical trial next year. That’s the kind of early traction investors watch closely. Full details here 👉 https://www.zacks.com/stock/news/2803792/atrc-treats-first-patients-using-novel-dual-energy-pfa-rfa-platform?cid=sm-stocktwits-2-2803792-teaser-24638&ADID=SYND_STOCKTWITS_TWEET_2_2803792_TEASER_24638
0 · Reply
Arcides
Arcides Nov. 30 at 5:35 PM
$ATRC chart is a mess, too much volatility, was this a shakeout?
0 · Reply
RunnerSignals
RunnerSignals Nov. 20 at 8:46 PM
mini-pulse pop! $AMZN $APTV $AR $ATRC $CYBR all waking up some bouncing some breaking and some just teasing. charts heating up… https://stocksrunner.com/news/2025-11-20-daily-market-pulse-advanced-technical-analysis
0 · Reply
maq34
maq34 Nov. 7 at 3:56 PM
$ATRC Raised 2025 Financial Outlook: Building on the strong results, AtriCure raised its full-year 2025 revenue projection to a range of $532 million to $534 million, and its adjusted EBITDA forecast to between $55 million and $57 million. PT of $54 and up…! $AMGN $ABBV $VRTX $GILD
0 · Reply
maq34
maq34 Nov. 7 at 3:53 PM
0 · Reply
maq34
maq34 Nov. 7 at 3:43 PM
$ATRC Attractive price with solid product offering $ABBV $ASTRAZEN.NSE
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 6 at 8:27 PM
$ATRC Share Price: $31.75 Contract Selected: Apr 17, 2026 $30 Calls Buy Zone: $3.31 – $4.09 Target Zone: $6.32 – $7.72 Potential Upside: 80% ROI Time to Expiration: 161 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
NJgolfer
NJgolfer Oct. 16 at 9:46 PM
$ATRC Underfollowed but showing buying signs with earnings a few weeks out. The current 9 week consolidation looks like a flat base as it has only corrected a total of 12.5% from H to L. Upside targets $43 and $44
0 · Reply
Doozio
Doozio Sep. 22 at 10:46 PM
$ATRC let da 🧠 spread during 🐒🍌🧠⏰♾️
0 · Reply
SilverEagle
SilverEagle Sep. 22 at 5:06 PM
$ATRC trying to bust through 3 months highs 👀
0 · Reply
SilverEagle
SilverEagle Sep. 9 at 9:55 PM
$ATRC monthly MAs starting to curl.
0 · Reply
Doozio
Doozio Sep. 8 at 3:00 PM
$ATRC during 🐒🍌🧠⏰♾️
0 · Reply
SignalMind
SignalMind Aug. 23 at 6:19 AM
$ATRC AtriCure Inc is a medical device company focused on atrial fibrillation with steady growth trajectory
0 · Reply
Winning_calls
Winning_calls Aug. 4 at 1:48 PM
$ATRC 😉
0 · Reply
Winning_calls
Winning_calls Aug. 4 at 3:25 AM
$ATRC pick me up @ $34
0 · Reply
JarvisFlow
JarvisFlow Jul. 30 at 11:00 AM
Needham has adjusted their stance on AtriCure ( $ATRC ), setting the rating to Buy with a target price of 44 → 45.
0 · Reply